+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: Hbmec cells, Primary antibody: P12066(PLXND1 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P12066(PLXND1 Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

The PLXND1 antibody targets Plexin-D1. a transmembrane receptor belonging to the plexin family, which plays critical roles in cell signaling and guidance during development. Plexin-D1 (encoded by the *PLXND1* gene) interacts with semaphorins, particularly class 3 semaphorins (SEMA3s), to regulate cellular processes such as angiogenesis, axon guidance, and immune cell migration. It is highly expressed in endothelial cells, where it governs vascular patterning by modulating cytoskeletal dynamics and cell adhesion. Dysregulation of PLXND1 has been implicated in pathological conditions, including cancer, atherosclerosis, and retinopathies, due to its role in promoting abnormal blood vessel growth or inflammation.

PLXND1 antibodies are essential tools for studying its expression, localization, and function in physiological and disease contexts. They are widely used in techniques like immunohistochemistry, Western blotting, and flow cytometry to assess protein levels in tissues or cultured cells. Researchers also employ these antibodies to investigate PLXND1's involvement in tumor angiogenesis, where its overexpression correlates with metastatic progression, or in cardiovascular diseases linked to endothelial dysfunction. Additionally, PLXND1-blocking antibodies are explored therapeutically to inhibit pathological vascular remodeling. Validation of antibody specificity, often via knockout controls or peptide competition assays, is crucial due to potential cross-reactivity with other plexin family members.